Genprex Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Acclaim-1 Phase 2a Interim Analysis Enrollment QuarterlyTarget: 19 patients enrolled
Acclaim-3 Phase 2 Interim Analysis Enrollment QuarterlyTarget: 25 patients enrolled
Cash and Cash Equivalents Quarterly18MTarget: Sufficient to fund operations into second half of 2027
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Implement a reverse stock split at a ratio between 1-for-5 and 1-for-50 as authorized by stockholders at the June 18, 2026 annual meeting.
- GPX-002 IND-Enabling Studies and ToxicologyAction: Finalize study designs, initiate toxicology studies, and scale up cGMP manufacturing with CDMO partners.
Research as of 20 Jun 2026